| # | Drug | Count |
|---|---|---|
| 0 | RITONAVIR | 19 |
| 1 | RITONAVIR 100 MG | 16 |
| 2 | DARUNAVIR | 12 |
| 3 | DOLUTEGRAVIR SODIUM | 11 |
| 4 | TENOFOVIR DISOPROXIL FUMARATE | 8 |
| 5 | EMTRICITABINE | 7 |
| 6 | DARUNAVIR 600 MG | 6 |
| 7 | DARUNAVIR 800 MG | 6 |
| 8 | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | 6 |
| 9 | ATAZANAVIR | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IBALIZUMAB | 4 | 0.0074 |
| 1 | DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE | 5 | 0.0018 |
| 2 | FOSCARNET SODIUM | 5 | 0.0012 |
| 3 | DOLUTEGRAVIR SODIUM | 11 | 0.0012 |
| 4 | RITONAVIR 100 MG | 16 | 0.0011 |
| 5 | DARUNAVIR 600 MG | 6 | 0.0010 |
| 6 | DARUNAVIR | 12 | 0.0008 |
| 7 | ETRAVIRINE | 3 | 0.0007 |
| 8 | DARUNAVIR ETHANOLATE AND COBICISTAT | 1 | 0.0006 |
| 9 | ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE | 3 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD4-directed Blocking Antibody [EPC] | 4 | 0.0074 |
| 1 | Protease Inhibitor [EPC] | 25 | 0.0006 |
| 2 | Cytochrome P450 3A Inhibitor [EPC] | 28 | 0.0005 |
| 3 | CCR5 Co-receptor Antagonist [EPC] | 1 | 0.0004 |
| 4 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 9 | 0.0004 |
| 5 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 29 | 0.0003 |
| 6 | Blood Viscosity Reducer [EPC] | 1 | 0.0002 |
| 7 | Antimalarial [EPC] | 2 | 0.0002 |
| 8 | Antiprotozoal [EPC] | 2 | 0.0002 |
| 9 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 9 | 0.0002 |